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Abstract
Inflammatory bowel disease (IBD) is a group of 
chronic multifactorial disorders. According to a recent 
study, the number of IBD association loci is increased 
to 201, of which 37 and 27 loci contribute specifically 
to the development of Crohn’s disease and ulcerative 
colitis respectively. Some IBD associated genes are 
involved in innate immunity, in the autophagy and in 
the inflammatory response such as NOD2 , ATG16L1  
and IL23R , while other are implicated in immune 
mediated disease (STAT3 ) and in susceptibility to 
mycobacterium infection (IL12B ). In case of early 
onset of IBD (VEO-IBD) within the 6th year of age, 
the disease may be caused by mutations in genes 
responsible for severe monogenic disorders such 
as the primary immunodeficiency diseases. In this 
review we discuss how these monogenic disorders 
through different immune mechanisms can similarly 
be responsible of VEO-IBD phenotype. Moreover we 
would highlight how the identification of pathogenic 
genes by Next Generation Sequencing technologies 
can allow to obtain a rapid diagnosis and to apply 
specific therapies.
Key words: Inflammatory bowel disease; Primary 
immunodeficiency disease; Early onset; Next gene-
ration sequencing; Genome wide association studies
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Core tip: Genetic investigation is of fundamental 
importance describing inflammatory bowel disease 
(IBD) as a complex disease, as well as in identifying 
the monogenic disorders that may present with IBD-
like features. Using third-generation technology 
should be leveraged to accelerate the screening and 
allow the identification of the most rare monogenic 
defects. Furthermore, the study of genetic variants in 
monogenic and in sporadic IBD could help unraveling 
the complex interplay between defective and com-
pensatory immune responses, opening the way to the 
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identification of new targets for therapy.
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INTRODUCTION
Inflammatory bowel disease (IBD) is the result of an 
unbalanced crosstalk between gut luminal content 
and the mucosal immune system. IBD encompasses 
a continuum of clinical disorders, ranging from Crohn’
s disease (CD) through indeterminate colitis (IC) to 
ulcerative colitis (UC). In fact, some patients may 
present significant clinical overlap between these forms 
and even develop one form from another. However, 
there are distinctive genetic, environmental and 
pathogenic factors that can be involved in the three 
forms.
In general, CD is characterized by changes in 
intestinal microbiota (dysbiosis), focal translocation of 
bacteria across the mucosal barrier, altered mucosal 
response to bacterial invasion, development of chronic 
granulomatous inflammation and activation of adaptive 
immunity as results of compensatory mechanisms 
to minor defects of innate immunity or autophagy. 
Genetic factors can involve variants of different groups 
of genes, leading to a leaky epithelial barrier and 
impaired mechanisms of phagocytosis and autophagy. 
Whatever is the particular combination of factors in 
each patient, the common result is a vicious circle of 
dysbiosis, granulomatous inflammation and activation 
of T cell immunity[1].
In contrast, a major role in UC seems to be 
played by dysregulation of lymphocyte immunity, 
with increased activation of T cells and/or reduced 
regulatory T cell function. Risk factors implicate a 
number of variants in genes associated with T cell 
activity and with down regulation of mucosal inflam­
mation.
Furthermore, intermediate forms of IBD can share 
various clinical and genetic features with both CD and 
UC[2,3]. Indeterminate colitis is particularly common 
among subjects with very early onset in the first years 
of life (VEO­IBD). Indeed, patients with VEO­IBD 
present quite distinctive clinical features and display 
worse clinical course and usually poorer response to 
treatments compared with adult onset disease.
Although genetic factors have been associated with 
different forms of IBD, the diagnosis in each subject is 
commonly based on clinical and histopathology data, 
rather than genetic results. Indeed, the particular 
profile of common genetic variants has little con­
sequences on the prediction of the disease course and 
response to treatments.
However, genetic analysis can have an important 
impact on clinical practice for VEO­IBD.
Monogenic disorders are believed to be very rare, 
but it is expected that in the severe form of earlier 
onset of IBD, genetic factors play a significant role 
in pathogenesis. In some cases, VEO­IBD can result 
from monogenic disorders such as primary immuno­
deficiency diseases (PID).
Several anecdotal reports showed that a number of 
PIDs can onset with a clinical presentation compatible 
with IBD. Taking into account this possibility can 
allow genetic confirmation and effective treatment 
with hematopoietic stem cell transplantation (HSCT), 
avoiding ineffective and dangerous treatments with 
immunosuppressant, biological inhibitors and even 
surgery. In most cases, the application of an integrated 
clinical, functional and genetic approach can allow the 
identification of some PID diagnosis, however clinical 
and functional signs can be unexpressed or overlooked 
and the correct genetic assay may be delayed. Thus, 
given the importance of the earliest detection of 
PID, we dedicated in this review a large space to the 
detailed description of monogenic forms of IBD. We 
also highlight the potential role of severe VEO­IBD.
In the first part of this review, we will discuss about 
the susceptibility to develop IBD followed by how the 
availability of improved genetic tools can impact on the 
early diagnostics of monogenic VEO­IBD.
In addition, the study of monogenic causes of 
IBD may provide significant information for a better 
understanding of sporadic adult onset disease. Indeed, 
the role of defective mucosal immunity in IBD is a 
fundamental unsolved question.
Increasing evidence support the idea that in most 
cases hyperactive intestinal inflammation can be the 
result of compensatory responses to the environment 
in presence of various immune defects. The study of 
genetic variants in monogenic and in sporadic IBD 
could help unraveling the complex interplay between 
defective and compensatory immune responses, 
opening the way to the identification of new targets for 
therapy.
In the second part of this review, we will discuss 
how defects in regulation of innate or adaptive 
immunity can be relevant to the pathogenesis of 
inflammation in IBD.
GENES INVOLVED IN MULTIFACTORIAL 
SUSCEPTIBILITY IBD
Until the last year several genome­wide associations 
studies (GWAS), followed by meta analysis of both 
principal forms of IBD (CD and UC) identified a total of 
163 IBD loci: 60 loci with heterogeneous effects while 
the effects of the other 50 loci were not distinguishable 
in CD or UC. The remaining 53 loci were specific only 
for CD (n = 30) or for UC (n = 23). A total of 113 of 
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the 163 IBD loci were shared with other complex traits 
such as immune mediated diseases and mycobacterial 
infection[4­6]. Recently by immunochip genotype data 
from both European and East Asian, Indian or Iranian 
cohorts implicate new 38 loci in IBD risk most of which 
(27 loci) contribute to both diseases (CD and UC) while 
of the remaining 11 loci, 7 were classified as specific to 
CD and 4 to UC[7].
The innate immune receptor nucleotide oligo­
merization domain containing 2 (NOD2) was the first 
gene associated with inflammatory bowel disease[8,9]. 
Three mutations (R702W, R703C and L1007fs) in the 
NOD2 coding region were demonstrated to be asso­
ciated with CD in Quebec affected patients that carried 
at least one variant[10].
In Hungarian CD patients, as well as in other 
countries, the three­mentioned NOD2 variant are 
associated with early onset and the presence of one 
variant allele increases the risk for developing CD from 
1.5 to 4.3 folds, while two variants alleles increase 
susceptibility to develop the disease from 20 to 40 
folds compared with the general population[11].
The mechanisms linking NOD2 variants to the 
risk of CD are not fully clear. In fact, these variants 
lead to loss­of­function of the protein, suggesting a 
link between an impaired innate immune response 
to bacterial infections and disease development[8,9]. 
In contrast, NOD2 gain­of­function mutations, in the 
NATCH domain of the receptor, are associated with 
Blau Syndrome (BS) and early onset Sarcoidosis 
(EOS), causing a rare autosomal dominant disease 
characterized by a triad of symptoms (rashes, uveitis 
and arthritis) and onset among 3 and 4 years of 
age[12,13].
Another strong association with CD regards the 
autophagy related 16­like 1 (ATG16L1) gene[14,15], 
while interlukin­23 receptor (IL23R) gene, results 
associated with both UC and CD[16].
Few GWAS have been performed also in pediatric 
patients: a study identified for the first time for 
pediatric IBD onset the TNFRSF6B gene within the 
20q13 and the PSMG1 gene within the 21q22 loci[17]. 
In early onset cases, an association was described 
between IL23R, STAT3, JAK2 and IL12B and CD[18,19].
Most of these genes concern the functions of innate 
immunity, autophagy and inflammatory cytokines 
production. In addition, the associations with HNF4A 
and GNA12 point out the role of defects of epithelial 
barrier function[20]. Moreover Kaser et al[21] identified 
an association among hypomorphic XBP1 variants 
with both IBD forms, reporting that the deletion in the 
intestinal epithelial cells induces spontaneous enteritis.
A study carried out on the Korean population 
proves the different genetics IBD among different 
populations. Several Korean children suffered from 
UC at the time of diagnosis showed diarrhea and 
hematochezia like the features in Western studies. In 
a particular way this study demonstrated that genetic 
of the IBD between the affected populations reflects 
the ethnic differences. In fact the NOD2 and ATG16L1 
variants, strongly associated with IBD in western 
populations, were not associated in the Korean IBD 
patients, who conversely displayed an association with 
three genes (ATG16L2, DUSP5 and TBC1D1) that 
aren’t associated in Western population[22].
Recently, new technologies allow expanding the 
possibility of genetic analysis in IBD. Indeed, Whole 
Exome Sequencing studies (WES) performed the 
identification of further genetic association with CD, 
including missense mutations in the PR domain­
containing 1 (PRDM1), that encodes a transcription 
factor expressed by T and B cells, and a common 
variation in Nuclear domain 10 protein 52 (NDP52), 
an adaptor protein that acts in selective autophagy of 
intracellular bacteria[23].
In addition, Xu et al[24] discovered in Chinese 
patients by WES novel genetic variants in the DLG1 
gene involved in cell proliferation, T cell polarity and T 
cell receptor signalling, as a susceptibility gene for CD.
MONOGENIC FORMS IN EARLY ONSET 
IBD
EO­IBD is defined by the onset of disease within the 6th 
year of age. This group includes neonatal IBD (first 28 
d of age), Infant and toddler onset IBD (younger than 
2 years, VEO­IBD), and early childhood groups[25].
In VEO­IBD, the disease tend to be much more severe 
and much more difficult to control with conventional 
therapies, compared with adult­onset IBD. Increasing 
evidence suggest a stronger genetic contribution to 
these forms compared with adults. Indeed some 
patients with VEO­IBD may have developed intestinal 
inflammation as part of a monogenic disease, usually 
a PID. In fact, these cases may account, at least in 
part, for the phenomenon of missing heritability in 
IBD, which is the inability to explain all the genetic 
contribution to IBD based solely on the additive effect 
of common risk gene variants[26]. Overall, at least 58 
genes can play a role in VEO­IBD (Table 1), in addition 
to those associated with susceptibility to multifactorial 
IBD. Most of these genes are the cause of very rare 
monogenic disorders that can present with clinical 
and histopathological features similar to IBD. The 
different diseases associated with early onset IBD­like 
symptoms have been recently reviewed elsewhere[27]. 
Distinguishing monogenic forms among VEO­IBD is a 
crucial importance to allow the best treatment. A panel 
of candidate genes used for the analysis of VEO­IBD 
can allow a timing diagnosis and an effective cure in 
many patients, as well as an epidemiologic definition 
of the real impact of PIDs in this field.
However, it is worth noting that most cases of 
VEO­IBD can still recognize a multifactorial origin, as 
suggested by the evidence of the increased incidence 
of early onset cases of IBD in recent decades, reaching 
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Gene Inheritance Chr OMIM Disease Clinical Features IBD-like Treatment Ref.
Hyper and autoinflammatory disorders
   MVK AR 12q24 #260920 Mevalonate kinase deficiency Abdominal pain, 
Diarrhea, vomiting
Anakinra [28,30-32]
   MEFV AR 16p13 #134610
#249100
Familial Mediterranean 
Fever
Diarrhea, abdominal 
pain, mucus in the stool, 
peritonitis
Colchicine [33,34]
   PLCG2 AD 16q23 #614878 Autoinflammation, antibody 
deficiency, and immune 
dysregulation syndrome
Bloody diarrhoea, UC, 
enterocolitis
[35]
   NLRP12 AD 19q13 #611762 Familial cold 
autoinflammatory 
syndrome 2
Abdominal pain Anakinra [37]
   NLRC4 AD 2p22 #616050 Autoinflammation with 
infantile enterocolitis
Neonatal-onset 
enterocolitis
Anakinra [38-40]
Immune regulation and dysregulation disorders (innate and adaptive immune responses)
   XIAP XL Xq25 #300635 X-linked lymphoproliferative 
syndrome 2
Perianal abscesses HSCT [41-44]
   STXBP2 AR 19p13 #613101 Familial haemophagocytic 
lymphohistiocytosis type 5
IDB-like colitis HSCT [45]
   HPS1 AR 10q23 #203300 Hermansky Pudlak 
syndrome (type 1, 4 and 6)
IBD, UC, Granulomatous 
colitis
Platelet transfusion
Anakinra
[46-50]
   HPS4 22q12 #614073 Granulomatous colitis Infliximab
   HPS6 10q24 #614075 Gastrointestinal 
symptoms, 
granulomatous colitis, 
imperforate anus, gluteal 
flap repairs
Subtotal colectomy
   FOXP3 XL Xp11 #304790 Immunodysregulation, 
polyendocrinopathy and 
enteropathy
Intractable diarrhea, total 
or subtotal intestinal 
villous atrophy, 
enteropathy
HSCT [51]
   AIRE AR/AD 21q22 #240300 Autoimmune 
Polyendocrinopathy 
Candidiasis Ectodermal 
Dystrophy
Malabsorption, diarrhea, 
chronic atrophic gastritis
No specific treatment is 
available
[52]
   IL10 1q32 *124092 IL-10 Signaling defects Severe early-onset 
enterocolitis
   IL10RA AR 11q23 #613148 Inflammatory Bowel 
Disease-28, early onset
Early onset enterocolitis, 
enteric fistula, perianal 
abscesses
HSCT [53-63]
   IL10RB AR 21q22 #612567 Inflammatory Bowel 
Disease-25, early onset
Early onset enterocolitis, 
perianal abscesses, 
enterocutaneous and 
rectovaginal fistula
Defects in phagocyte bacterial killing and neutropenia
   SLC37A4
   GSD-1b
AR 11q23 #232220 Glycogen storage disease 1b Perioral and perianal 
lesions, ileitis, colitis, 
CD-like, protuberant 
abdomen
Granulocyte colony 
stimulating factor, 
prophylactic oral iron
[64-66]
   G6PC3 AR 17q21 #612541 Severe Congenital 
neutropenia 4
Diarrhea, colitis, 
abdominal pain, perianal 
fistula or abscess, CD-like, 
oral aphthous ulceration
Granulocyte colony 
stimulating factor
[67]
   ITGB2 AR 21q22 #116920 Leucocyte adhesion
deficiency 1
CD-like with 
discontinuous stomatitis, 
ileocolitis, perianal and 
rectal abscess, fistulas, 
adhesion, strictures
HSCT [70,71]
   NCF1 AR 7q11 #233700 Chronic granulomatous Colitis, perirectal abscess HSCT [70-75]
   NCF2 AR 1q25 #233710 disease Perirectal abscesses due 
to immunodeficiency
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   NCF4 AR 22q12 #613960 Chronic granulomatous 
colitis, diarrhea perianal 
infections, erosions and 
ulceration of the gastric 
fundus and colonic 
mucosa, multiple small 
granulomata on colonic 
biopsy.
   CYBA AR 16q24 #233690 Perirectal abscesses due 
to immunodeficiency
   CYBB XL Xp11 #306400 Gastrointestinal 
perirectal abscesses due 
to immunodeficiency, 
enteritis and colitis
T and B lymphocyte selection activation defects
   WAS XL Xp11 #301000 Wiskott-Aldrich Syndrome Diarrhea, hematemesis 
and melena
IBD, UC like, colonic 
inflammation with crypt 
abscess
HSCT/transfusion of 
autologous genetically 
modified
[77-79]
   DCLRE1C AR 10p13 #603554
 #602450
Omenn Syndrome; 
Athabascan-type severe 
combined immunodeficiency
Chronic diarrhea HSCT [25,80-82,85,86]
   RAG1 AR 11p12 4 Omenn Syndrome
   RAG2 AR #603554
   LIG4 AR 13q33 #606593 LIG4 Syndrome Protracted diarrhea HSCT
   ADA AR 20q13 #102700 Partial adenosine deaminase 
deficiency
Enzyme replacement 
therapy using frozen 
irradiated red blood 
cells/HSCT
HSCT
   IL2RG XL Xq13 #300400
 #312863
Severe Combined 
Immunodeficiency; 
Moderate Immunodeficiency
   CD3G AR 11q23 #615607 Immunodeficiency 17 Diarrhea autoimune, 
gastroenteritis, recurrent, 
enteropathy
HSCT
   ZAP70 AR 2q11 #269840 Selective T-cell defect Diarrhea HSCT
   LCK AR 1p35 #615758 Immunodeficiency 22 Darrhea autoimmune, 
panniculite
HSCT [83,84]
   LRBA AR 4q31 #614700 Common variable 
immunodeficiency 8
Colitis, IBD Ig replacement therapy/
HSCT
[88,90,91]
   ICOS AR 2q33 #607594 Common variable 
immunodeficiency 1
Early onset 
gastrointestinal tract 
infections, enteritis, 
recurrent diarrhea
Ig replacement therapy/ 
HSCT
[92]
   IL21 AR 4q27 # 615767 IL-21 deficiency Early onset IBD Ig replacement therapy/
HSCT
[93]
   CTLA-4 AD 2q33 #616100 Autoimmune 
lymphoproliferative
syndrome type V
Early onset IBD and 
autoimmunity
No specific treatment is 
available
[122]
   TNFRSF13B AR/AD 17p11 #240500 TACI deficiency Enteritis, recurrent 
diarrhea
Ig replacement therapy/
HSCT
[94]
   COG6 AR 13q14 #614576 Congenital disorder of 
glycosylation, type Ⅲ
Anal anteposition, 
recurrent diarrhea, IBD
No specific treatment is 
available
[123]
   BTK XL Xq22 #300755
#307200
Agammaglobulinemia
Isolates growth hormone 
deficiency type Ⅲ
Diarrhea Ig replacement therapy/
HSCT
[99,100]
   PIK3R1 AR 5q13 #615214 Agammaglobulinemia 7 Recurrent gastroenteritis [101]
   CD40LG XL Xq26 #308230 Immunodeficiency with 
hyper-IgM type Ⅰ
Diarrhea [96,97]
   AICDA AR 12p13 #605258 Immunodeficiency with 
hyper-IgM type Ⅱ
Gastrointestinal tract 
infections
[98]
Disorder of apoptosis
   CASP8 AR 2q33 #607271 Caspase 8 deficiency chronic diarrhea No specific treatment is 
available
[102]
   ITCH AR 20q11 #613385 Autoimmune disease, 
multisystem with facial 
dysmorphism
Enteropathy, chronic 
diarrhea, malabsorption, 
gastrostomy tube feeding
Immunosuppressive 
treatment
[112]
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4.37 per 100000 children[25].
Below we discuss how monogenic disorders 
involving different immune mechanisms can similarly 
be responsible for VEO­IBD.
Hyper and autoinflammatory disorders
A chronic or episodic inflammatory disease of the 
intestine can occur as part of a complex clinical picture 
in subjects affected by several autoinflammatory 
disorders.
Mevalonate kinase deficiency (MKD) is an auto­
somal recessive disease caused by mutations in the 
MVK gene and it is characterized by febrile attacks 
associated with diarrhea, vomiting and abdominal 
pain. The occurrence of abdominal pain and diarrhea, 
sometimes with blood and mucus, together with 
leukocytosis, chronic anemia and increased CRP could 
raise the suspicion of IBD[28]. In most cases intestinal 
inflammation occurs only during febrile flares, yet the 
use of glucocorticoids can hidden the typical periodicity 
of the disease, reducing the severity but increasing the 
frequency of symptoms, thus making more difficult 
the diagnosis[29]. In some cases, patients with MKD 
may present with VEO­IBD with the characteristics of 
indeterminate colitis. Of note, treatment with anti­IL­1 
agents can allow relieving inflammatory colitis as well 
as other febrile and inflammatory features typical of 
the disease[30­32].
IBD can be also more frequent and severe in 
patients with MEFV mutations. Identification of MEFV 
can allow diagnosis of Familial Mediterranean Fever 
and effective treatment with colchicine[33,34].
   MASP2 AR 1p36 #613791 MASP2 deficiency IBD, UC-like [113]
WELL defined syndromes associated with EO-IBD
   TTC7A AR 2p21 #243150 Multiple intestinal atresia Multiple areas of atresia 
along the small and large 
intestines,
Intestinal malrotation
Intraluminal calcification, 
bowel distention Mucous 
membrane ulceration
Surgery [103-105]
   TTC37 AR 5q15 #222470 Trico hepato enteric 
syndrome
Diarrhea, severe villous 
atrophy
Parenteral nutrition [107,108]
   SKIV2L AR 6p21 #614602 Trico hepato enteric 
syndrome 2
Diarrhea, colitis, severe 
and intractable villous 
atrophy
Ig supplementation [106]
   NEMO/
   IKBKG
XL Xq28 *300248 X-linked ectodermal 
dysplasia and 
immunodeficiency
CD-like colitis, villous 
atrophy, recurrent 
digestive tract infections, 
intractable diarrhea and 
recurrent ulcerations
HSCT [109,110]
   GUCY2C AD 12p13 #614616 Familial Diarrhea Early onset chronic 
diarrhea, IBD, CD, small-
bowel obstruction, 
esophagitis, irritable 
bowel syndrome, ileal 
inflammation, abdominal 
pain
Parenteral nutrition [111]
Defects affecting the integrity of intestinal barrier
   COL7A1 AR 3p21 #226600 Dystrophic epidermolysis 
bullosa
Gastrointestinal 
complications, diarrhea, 
colitis, esophageal blisters 
strictures, anal blisters, 
constipation
Immuno myeloablative 
chemotherapy and 
allogenic HSCT
[114]
   ADAM17 AR 2p25 #614328 Neonatal inflammatory skin 
and bowel disease 1
Perioral and perianal 
erythemas with fissuring, 
diarrhea, malabsorption, 
plasma cell duodenitis 
crypt hyperplasia, villous 
atrophy
EGFR Ligands [115]
   FERMT1/
   KIND1
AR 20p12 #173650 Kindley syndrome Intestinal involvement 
with haemorrhagic 
diarrhoea, UC
No specific treatment is 
available
[116]
   EGFR AR 7p11 #616069 Neonatal inflammatory skin 
and bowel disease 2
Diarrhea No specific treatment is 
available
[117,118]
   TGFBR1 AD 9q22 #609192 Loeys-Dietz syndrome, 
type 1
Gastrointestinal 
disorders,
Medication and 
preventative surgery
[119]
   TGFBR2 AD 3p24 #610168 Loeys-Dietz syndrome, 
type 2
IBD: Inflammatory bowel disease; UC: Ulcerative colitis; HSCT: Hematopoietic stem cell transplantation; CD: Crohn's disease.
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Recently, a de novo missense mutation (S707T) 
in the PLCG2 gene has been detected by the exome 
analysis in two patients suffering from an autosomal 
dominant inflammatory disorder with severe enterocolitis 
and mild immunodeficiency, even if it is not clear 
whether gut inflammation is facilitated by the hyper­
inflammatory defect or by the immunodeficiency[35].
Familial cold autoinflammatory syndrome­2, a 
systemic auto­inflammatory disease caused by hetero­
zygous mutations in the NLRP12 gene can present 
abdominal pain vomiting and buccal aphthous ulcers 
together with cold­induced fever[36] and in some cases 
hypogammaglobulinemia[37].
Familial cold autoinflammatory syndrome 4 is an 
autosomal dominant disease caused by heterozygous 
mutation in the NLRC4 gene and characterized by 
intermittent episodes of rash, arthralgia, and fever after 
exposure to cold[38]. Recently a family was reported 
with a syndrome featuring neonatal onset enterocolitis, 
in which the father and two respective sons carried 
a missense mutation (V341A) in the NLRC4 gene. It 
has also been shown that this mutation, functionally 
associated with gain of function, cosegregates in the 
family with the disease[39].
Canna et al[40] report a de novo missense sub­
stitution (T337S) on NLRC4 NBD domain that causes 
early onset recurrent fever flares and macrophage 
activation syndrome (MAS).
Defect of cytotoxicity and hyperinflammation
The association of inflammatory enterocolitis with MAS 
can be found also in subjects with XIAP mutations, 
as described by Worthey[41]. Indeed, XIAP deficiency, 
already associated with X­linked lymphoproliferative 
syndrome­2 (XLP2), can be the cause of Crohn’s like 
features in the absence of MAS[42]. In particular, Zeissig 
et al[43] identified XIAP private variants in absence of 
symptoms related to XLP2 in a cohort of German boys 
with early onset CD. Of note, macrophage activation 
in subjects with XIAP deficiency is a compensatory 
phenomenon sustained by Interferon­γ production 
by lymphocytes and natural killer cells with impaired 
antiviral capacity, thus it is not of autoinflammatory 
origin. Similarly, the development of Crohn’s­like 
disease seem to be due to a deficiency rather than 
to an excess of XIAP function, leading to defective 
activation of NOD2 in monocytes. In contrast to 
lymphohistiocytosis, IBD has been reported also in 
female subjects heterozygous for XIAP mutations[44].
Inflammatory colitis has been reported also in 
anecdotal cases of subjects with X­linked lympho­
proliferative syndrome, although in this case the 
mechanisms are unknown[45].
Hermansky­Pudlak syndrome (HPS) is a rare 
autosomal recessive disease characterized by typical 
syndromic features including albinism, hemorrhagic 
diathesis, and pigmented reticuloendothelial cells. The 
HPS patients with specific mutations in the respective 
genes (HPS-1, HPS-4, HPS-6) have major organ 
involvement including also severe granulomatous 
colitis with pathologic features suggestive of CD[46­50].
Immune regulation and dysregulation disorders (innate 
and adaptive immune responses)
Autoimmune enteropathy is part of the X­linked 
immune dysregulation, polyendocrinopathy, entero­
pathy disease and it is caused by FOXP3 gene 
mutations. Although the disorder has distinctive 
features making it well distinguishable from IBD, 
mutation in FOXP3 have been recently associated with 
very­early IBD phenotype[51].
Autoimmune enteropathy has been described, 
albeit more rarely, also in the autoimmune polyen­
docrinopathy syndrome type[52].
In recent years, several studies highlighted the 
causative role of the immunoregulatory cytokine 
IL-10 and of its receptor in the early onset IBD[53­62] 
and the genetic analysis of IL-10, IL10RA, IL10RB 
has became routinely in patients who developed the 
first symptoms within the 3 mo of life, regardless of 
parents’ consanguinity[63].
Defects in phagocyte bacterial killing and neutropenia
Neutrophil defects are often associated with intestinal 
inflammation. In particular, subjects with glycogen 
storage disease­type 1b show neutrophil dysfunction 
and run increased risk of developing Crohn’s Disease­
like[64­66].
In a similar manner, subjects with defect of G6PC3, 
often develop CD­like inflammation, which is also 
associated with persistent T cell lymphopenia[67].
Other neutrophil defects associate with early onset 
IBD include Leukocyte Adhesion Deficiency­1 (LAD­1, 
ITGB2 mutated), which can be associated with chronic 
ileocolitis[68], early onset ulcerative colitis and a non­
specific Crohn’s like colitis[69] as well as with bacterial 
infections.
However, the best characterized defect of pha­
gocytes associated with VEO­IBD is chronic gra­
nulomatous disease (CGD), both in its X­linked 
and autosomal recessive forms. Severe infections 
by catalase positive bacteria and fungi are usually 
prominent clinical features, however, cases presenting 
first with intestinal inflammation, often in the first 
months of life, are not rare, in particular among 
subjects with autosomal recessive CGD[70­73]. IBD in 
subjects with CGD reproduces the clinicopathological 
features of CD[74]. Recently, Dhillon et al[75] found 
some variants in heterozygosis in NADPH complex 
genes not leading to appreciable immunodeficiency, 
yet associated with susceptibility to VEO­IBD. Actually, 
the pathogenesis of inflammation in CGD could also 
be attributed to a deficiency of autophagy, leading 
to autoinflammatory response dominated by IL­1 
release[76].
T and B lymphocyte selection and activation defects
Intestinal inflammation is a common feature in several 
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PID affecting adaptive immunity.
Wiskott Aldrich Syndrome, an X­linked PID due 
to mutation in WASP protein, can often present with 
neonatal or infantile hemorrhagic and inflammatory 
colitis that can occur before other typical signs such 
as dermatitis and infections[77,78]. Thrombocytopenia 
with small platelets and in some cases also hypogam­
maglobulinemia usually with normal/high­IgA can help 
addressing the correct diagnosis[79].
Severe combined immunodeficiency (SCID) is often 
followed by enteropathy and failure to thrive, even 
before infections. In some cases a low lymphocyte 
count per age can raise the suspicion of SCID. 
However, in other cases with hypomorphic mutations 
in SCID associated genes, such as DCLRE1C, RAG1, 
RAG2, LIG4, ADA, IL2RG, CD3G, ZAP70 and LCK, 
lymphocyte count can be normal due to the develo­
pment of dysfunctional lymphocytes[25,80­84]. Rarely, a 
leaky SCID may present for years with IBD only, in the 
absence of severe infections. The presence of other 
signs such as severe eczematous rash should raise the 
suspicion of a SCID[81,85].
In all these cases only the analysis of lymphocyte 
subsets, and in particular of recent thymic emigrants 
(or the molecular measure of T cell receptor excision 
circles) can assist the correct diagnosis[86].
Common variable immunodeficiency (CVID) is 
also associated with intestinal inflammation, but the 
disease rarely occurs in the first years of life[87,88]. 
The development of IBD seems to be favorished by 
dysregulation of T­cells derived cytokines[89]. 
Although the CVID is a polygenic disease, there 
are a low percentage of cases due to specific genetic 
defects such as LPS­responsive beige­like anchor 
(LRBA), ICOS and IL-21, which may often present with 
earlier onset in life.
In particular, deficiency of the LRBA gene has been 
found in patients affected by CVID with early onset 
hypogammaglobulinemia, inflammatory bowel disease 
and autoimmune cytopenia[88,90]. Serwas et al[91] re­
cently identified a new missense mutation in the LRBA 
gene in a young girl with severe early IBD­like disease 
without other manifestations of immunodeficiency.
Other forms of CVID associated with IBD include 
deficiencies of ICOS gene, CTLA-4, PD-1, IL-21, 
TNFRSF13B and COG6[92­95].
IBD­like phenotype was observed also in patients 
with hyper­IgM syndrome resulting from defects in the 
CD40 ligand[96,97], AID genes[98] and in subjects with 
agammaglobulinemia due to defects in BTK[99,100] or 
PIK3R1[101].
Disorders of apoptosis
Several cellular mechanisms such as the embryonic 
development, cell differentiation and the elimination 
from the intestine and from other body parts are 
regulated by the caspases that are cysteine proteases. 
Caspase dysfunction has been associated with IBD, 
in particular CASP­8 is involved in the inflammation 
of the mucosa and controls in the CD patients the 
necroptosis of the Paneth cells and the death of the 
epithelial cells[102].
Well defined syndromes associated with early onset IBD
The multiple intestinal atresia (MIA) combined with 
SCID, is caused by mutations in the TTC7A gene[103]. 
Recently MIA was reported in different families with a 
very early onset form of apoptotic enterocolitis[104,105].
Another immunodeficiency associated with low 
numbers of B cells and immunoglobulins is the Tricho 
Hepato Enteric Syndrome, a syndromic diarrhea 
usually associated with mutations in the TTC37 or in 
the SKIV2L gene[106­108].
X­linked anhidrotic ectodermal dysplasia with 
immunodeficiency, caused by hypomorphic mutations 
in the nuclear factor­kB essential modulator (NEMO), 
is associated both with epithelial and immune defects. 
Except for syndromic features of ectodermal dysplasia 
and susceptibility to infection from various pathogens, 
patients often present severe chronic colitis, which in 
some cases has been reported to worsen after HSCT, 
probably depending on the engraftment of donor 
immune cells on the background of defective host 
epithelial cells[109,110].
Other syndromes with early onset chronic diarrhea 
intestinal inflammation comprise defects of GUCY2C, 
an intestinal receptor for the heat stable bacterial 
enterotoxins[111], ITCH, involved in the ubiquitin­editing 
protein complex[112], and MASP2 which is an important 
bactericidal factor[113].
Defects affecting the integrity of intestinal barrier
Mutations in the type Ⅶ collagen gene (COL7A1) 
induced the dystrophic epidermolysis bullosa, a geno­
dermatosis. IBD can develop both from mutations in 
COL7A1 and from acquired defects in this protein due 
to autoimmunity[27,114].
Other molecules involved in the intestinal barrier 
include ADAM17A, which has been associated to an 
autosomal neonatal recessive syndrome characterized 
by inflammatory skin and bowel disease[115].
Recessive mutations in KIND1/FERMT1 gene are 
responsible for Kindler syndrome, characterized by 
skin blistering, poikiloderma, photosensitivity and 
sometimes UC­like gastrointestinal symptoms and 
haemorrhagic diarrhea[116].
EO­IBD can be observed also in patients with EGFR 
deficiency, together with skin disease[117,118].
More complex is probably the pathogenesis of 
IBD in Loeys­Dietz syndrome, an autosomal disease 
caused by mutations in the TGFBR1 and TGFBR2 
genes that encode respectively for the receptor type 1 
and 2 of the transforming growth factor β[119].
CONCLUSION
When we are faced with a patient with symptoms 
related to chronic inflammatory bowel disease, it is 
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essential to consider first both the age of onset and 
the severity of symptoms just to find out whether the 
patient is suffering from classical multifactorial IBD 
or if we are facing a severe clinical case, potentially 
caused by a monogenic form, as which characterized 
by a more severe phenotype and resistant to tra­
ditional therapies. This first classification is critical 
to guide genetic investigation. The identification of 
monogenic forms, that are quite rare, can have high 
impact on the therapeutic options, with particular 
reference to hematopoietic stem cell transplantation. 
Thus, in case with early onset and severe or atypical 
features, the genetic research should be directed 
toward the identification of a mendelian form of the 
disease. Target sequencing of multiple candidate 
genes can be accomplished with technologies such as 
the ION TORRENT, which are now available in many 
laboratories. The target sequencing must be designed 
to analyze all those genes that up to that time have 
been identified associated with a particular phenotype 
with severe early onset. In cases with high suspicion of 
a mendelian cause, but with normal target sequencing 
results, a more complete and sensitive analysis can 
be performed by comparison of the patients’ whole 
exome sequence with that of their parents and/or 
relatives[120].
When a monogenic disorder underlying intestinal 
inflammation is detected, we should discard the 
diagnosis of IBD and refer to IBD­like inflammation. 
This is easy and correct when we are dealing with well­
defined PID, such as Wiskott Aldrich disease or chronic 
granulomatous disease. The distinction is much more 
tricky when we found other immune defects, such as 
those involving XIAP or LRBA.
An easy distinction could be based on the functional 
consequences of the genetic defect. It has been 
proposed that cases with lack of immunity should be 
indicated as PID, whilst the diagnosis of IBD should 
be reserved to cases with hyper­response of innate 
and adaptive immunity. However, it has been argued 
that excessive or defective immune responses can 
lead to similar inflammatory disorders, highlighting 
the importance of a proper functioning of immunity 
for intestinal homeostasis[121]. What makes even more 
complicated the clinical picture, is the fact that, a 
continuum may exist between severe defect, leading 
to both infections and inflammation signs, and mild 
defect, presenting only inflammatory signs.
Molecular genetics can help distinguishing inborn 
defects with excessive or defective immunity but, 
even more importantly, allow to discriminate defects 
expressed only in hematopoietic­derived cells from 
defect with an important role also in intestinal 
epithelium. In the first case (e.g., in subjects with 
neutropenias, Wiskott Aldrich disease and chronic 
granulomatous disease) HSCT is able to cure both 
the immunodeficiency and gut inflammation; in the 
second case (e.g., defects of NEMO, NOD2) HSCT can 
be ineffective. More difficult is to predict the success 
of HSCT in other disorders in which the genetic defect 
can be important both in hematopoietic­derived cells 
and epithelia.
In brief, inflammatory bowel disease can be the 
result of different genetic mechanisms leading to 
common inflammatory phenotypes and requiring 
similar treatments. VEO­IBD is often resistant to con­
ventional treatment.
Finding the molecular cause in single individuals 
could open the way to the development of novel and 
more specific therapeutic approaches.
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